Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2021 Net Income-$4.53M-$4.53MN/M vs Q3 2021 EPS Diluted-$0.22-$0.22N/M vs Q3 2021 Operating Income-$4,538,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
ended Sep 30, 2022 · filed Nov 4, 2022 · 35 d after period end